Detection reagent and kit for detecting male infertility caused by acrosin binding protein ACRBP mutation
By detecting the c.1091T>C site of the ACRBP mutant gene, nucleic acids, markers, detection reagents and kits for diagnosing sperm acrosome abnormalities were developed, which solved the problem that the sperm acrosome abnormalities could not be accurately predicted in the prior art. A highly accurate diagnosis of male infertility has been achieved, reducing the stress of patients and families.
Patent Information
- Application Number
- CN202411322471.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-23
- Publication Date
- 2024-12-03
AI Technical Summary
The existing technology lacks accurate methods to predict whether sperm has acrosomal abnormalities, resulting in long-term infertility in male infertility patients, which brings huge psychological and economic pressure to them and their families.
Develop a nucleic acid, marker, detection reagent and kit for detecting ACRBP mutations. By detecting the c.1091T>C site of the ACRBP mutation gene, it diagnoses male infertility caused by sperm acrosome abnormalities, with high diagnosis. Specificity and accuracy.
Effectively diagnose male infertility caused by sperm acrosome abnormalities, improve the accuracy and specificity of the diagnosis, and help patients and families relieve psychological and economic stress.
Smart Images

Figure BDA0005054385920000141 
Figure BDA0005054385920000142 
Figure BDA0005054385920000143
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of reproductive medicine technology, and specifically relates to a detection reagent and a kit for detecting male infertility caused by acrosome binding protein ACRBP mutation. More specifically, the present invention relates to an isolated nucleic acid, an expression vector, a recombinant cell, a marker, a detection reagent and a kit and uses thereof. Background Art
[0002] Fertilization is a key step in successful human reproduction, including multiple stages such as oocyte and sperm maturation, sperm capacitation, superactivation, acrosome reaction, sperm binding to zona pellucida, gamete fusion, egg activation and sperm disaggregation. Problems at any stage may lead to reproductive failure. Among them, sperm acrosome abnormality is one of the main causes of unexplained male infertility. Although routine examination of semen of such patients may show normal or only mild to moderate oligoasthenozoospermia, they may fail to fertilize completely or have a fertilization rate of less than 30% in in vitro fertilization. At present, the causes of sperm acrosome abnormalities are still poorly understood, and there is no accurate method to predict whether sperm has acrosome abnormalities. This leads to long-term infertility or failure of in vitro fertilization in patients, which brings great psychological pressure and economic burden to them and their families.
[0003] The acrosome of mammalian sperm is a cap-shaped vesicle located on the apical surface of the head. The lumen of the acrosomal vesicle is surrounded by an inner acrosomal membrane and an outer acrosomal membrane, containing soluble and acrosomal matrix components. The acrosome reaction is a process in which the outer acrosomal membrane and the oocyte plasma membrane fuse at multiple locations. The sperm serine protease acrosin (ACR) localized in the acrosomal matrix plays a crucial role in the dispersion of acrosomal matrix components. Since only sperm undergoing the acrosome reaction can fuse with the oocyte plasma membrane, the acrosome reaction is physiologically essential for fertilization. The acrosomal protein ACRBP is a specific binding protein for the ACR precursor (proACR) and intermediate forms. ACRBP is usually expressed only in the testis, but is also expressed in many different types of tumors, including bladder cancer, breast cancer, liver cancer, and lung cancer. Mammalian ACRBP is initially synthesized in spermatogenic cells as a precursor protein (ACRBP-W) of approximately 60 kDa. During spermatogenesis and / or epididymal maturation, the N-terminus of the precursor ACRBP-W is removed to produce a mature ACRBP (ACRBP-C) of 32 kDa. Acrbp knockout male mice show severe fertility decline, mainly due to abnormal acrosome formation. Although the pro-acrosomal vesicles can be assembled normally, early spermatids are unable to form large acrosomal granules, resulting in acrosomal structure fragmentation, which further leads to abnormal roundness and decreased motility of the epididymal sperm of Acrbp knockout male mice. Therefore, ACRBP plays a key role in the formation and configuration of acrosomal granules to the center of the acrosomal vesicle during early spermatogenesis. Therefore, it is urgent to develop a detection reagent and related kit related to male infertility caused by sperm acrosome abnormalities. Summary of the invention
[0004] The present invention aims to solve at least one of the technical problems existing in the prior art to a certain extent. To this end, the present invention provides an isolated nucleic acid, a marker, a detection reagent and a kit for detecting male infertility caused by sperm acrosome abnormality. The isolated nucleic acid of the invention can be used as a marker for diagnosing male infertility caused by sperm acrosome abnormality. By detecting the marker, it is possible to effectively diagnose whether a patient suffers from male infertility caused by sperm acrosome abnormality. The detection reagent and kit for detecting the above-mentioned marker have the advantages of high diagnostic specificity and high accuracy.
[0005] The present invention is accomplished based on the following findings of the inventors:
[0006] Chinese patent document CN115074431A discloses the use of IQCN as a target in the diagnosis and treatment of complete fertilization failure, and the allele mutations of IQCN are c.1067C>G, c.316A>G and c.1892C>A. This mutation can destroy the five IQ1 domains of the IQCN protein and cause the loss of the C-terminal sequence, resulting in acrosome defects in human sperm, and then causing male infertility. Chinese patent document CN115232198A This application discloses a polypeptide, which is a truncation of the IQCN protein, and the truncation of the IQCN protein is related to the phenotype of fertilization failure. The above inventions all provide an effective way for genetic diagnosis, prenatal genetic screening and genetic counseling for male patients with fertilization disorders.
[0007] Furthermore, the inventors found that acrosomal protein ACRBP is a gene related to male reproductive function, and its mutation may lead to sperm acrosome abnormality. However, there is no report on the mutation site of ACRBP gene and its use in genetic diagnosis of patients with sperm acrosome abnormality.
[0008] Based on this, in the first aspect of the present invention, the present invention provides an isolated nucleic acid. According to an embodiment of the present invention, the isolated nucleic acid includes an ACRBP mutant gene; wherein, compared with the ACRBP gene shown in the nucleotide sequence of SEQ ID NO: 1, the mutation site of the ACRBP mutant gene is c.1091T>C. The isolated nucleic acid according to an embodiment of the present invention can be used as a marker for diagnosing male infertility caused by sperm acrosome abnormalities, and by detecting the marker, it is possible to effectively diagnose whether a patient suffers from male infertility caused by sperm acrosome abnormalities.
[0009] According to an embodiment of the present invention, the isolated nucleic acid can be used as a marker for diagnosing male infertility caused by sperm acrosome abnormalities.
[0010] In a second aspect of the present invention, the present invention provides an expression vector. According to an embodiment of the present invention, the expression vector carries the isolated nucleic acid described in the first aspect.
[0011] In a third aspect of the present invention, the present invention provides a recombinant cell. According to an embodiment of the present invention, the recombinant cell carries the isolated nucleic acid described in the first aspect of the invention or the expression vector described in the second aspect of the invention.
[0012] According to an embodiment of the present invention, the recombinant cell is obtained by introducing the expression vector into a host cell.
[0013] The fourth aspect of the present invention is the use of the isolated nucleic acid described in the first aspect of the present invention as a marker for diagnosing male infertility caused by sperm acrosome abnormalities.
[0014] In a fifth aspect of the present invention, the present invention provides a marker. According to an embodiment of the present invention, the marker includes at least one of the following mutant genes: an ACRBP mutant gene, and compared with the ACRBP gene shown in the nucleotide sequence of SEQ ID NO: 1, the mutation site of the ACRBP mutant gene is c.1091T>C. The marker of the embodiment of the present invention can effectively diagnose whether the patient suffers from male infertility caused by sperm acrosome abnormality, and the detection reagents and kits for detecting the above markers have the advantages of high diagnostic specificity and high accuracy.
[0015] In a sixth aspect of the present invention, the present invention provides a detection reagent. According to an embodiment of the present invention, the detection reagent comprises the isolated nucleic acid described in the first aspect of the invention or the marker reagent described in the fifth aspect of the invention. The detection reagent according to the embodiment of the present invention can effectively diagnose male infertility caused by sperm acrosome abnormalities, and has the advantages of high diagnostic specificity and high accuracy.
[0016] According to an embodiment of the present invention, the reagent is a primer set for detecting ACRBP mutant gene.
[0017] According to an embodiment of the present invention, the primer set includes at least one of the following primer pairs:
[0018] Upstream primer GCTGGTGATAAAGATTTGGG and downstream primer TAGATACCTGGTTGCCGATG.
[0019] In a seventh aspect of the present invention, the present invention provides a kit. According to an embodiment of the present invention, the kit comprises the detection reagent according to the sixth aspect of the invention. The detection reagent according to the embodiment of the present invention can effectively diagnose male infertility caused by sperm acrosome abnormality, and has the advantages of high diagnostic specificity and high accuracy.
[0020] According to an embodiment of the present invention, the kit further comprises at least one of the following reagents:
[0021] dNTPs, Taq enzyme and PCR reaction buffer.
[0022] In an eighth aspect of the present invention, the present invention provides a use of the detection reagent described in the sixth aspect or the kit described in the seventh aspect in the preparation of a diagnostic product, wherein the diagnostic product is used to diagnose male infertility caused by sperm acrosome abnormalities. The detection reagent and kit according to the embodiments of the present invention can effectively diagnose male infertility caused by sperm acrosome abnormalities, and have the advantages of high diagnostic specificity and high accuracy. BRIEF DESCRIPTION OF THE DRAWINGS
[0023] Figure 1It is a screenshot of Sanger sequencing of the ACRBP gene c.1091T>C homozygous mutation and no mutation in Example 3 of the present invention. DETAILED DESCRIPTION
[0024] The embodiments of the present invention are described in detail below. The embodiments described below are exemplary and are only used to explain the present invention, and should not be understood as limiting the present invention.
[0025] It should be noted that the terms "first" and "second" are used for descriptive purposes only and should not be understood as indicating or implying relative importance or implicitly indicating the number of the indicated technical features. Therefore, the features defined as "first" and "second" may explicitly or implicitly include one or more of the features. Further, in the description of the present invention, unless otherwise specified, the meaning of "plurality" is two or more.
[0026] In this document, the terms “contain”, “include” or “comprise” are open expressions, that is, they include the contents specified in the present invention but do not exclude other contents.
[0027] As used herein, the terms "optionally", "optional" or "optionally" generally mean that the subsequently described event or circumstance may but need not occur, and that the description includes instances where the event or circumstance occurs and instances where it does not.
[0028] In this article, the term "expression vector" generally refers to a nucleic acid molecule that can be inserted into a suitable host and replicates itself, and the inserted nucleic acid molecule is transferred to a cell or host and / or between cells or hosts. The expression vector may include an expression vector that is mainly used to insert DNA or RNA into a cell, an expression vector that is mainly used to replicate DNA or RNA, and an expression vector that is mainly used to transcribe and / or translate DNA or RNA. The expression vector also includes a vector with a variety of the above functions. The vector can be a polynucleotide that can be transcribed and translated into a polypeptide when introduced into a suitable cell or host. Typically, the vector can produce a desired expression product by culturing a suitable cell or host that contains the vector.
[0029] In this article, the term "recombinant cell" generally refers to the use of genetic engineering technology or cell fusion technology to modify or reorganize the genetic material of the host cell to obtain a cell with a unique trait of stable inheritance. Among them, the term "host cell" refers to a prokaryotic cell or eukaryotic cell into which a recombinant vector can be introduced. The terms "transformed" or "transfected" used herein refer to the introduction of nucleic acids (such as vectors) into cells by various techniques known in the art. Suitable host cells can be transformed or transfected with the DNA sequence of the present invention, and can be used for the expression and / or secretion of target proteins. Examples of suitable host cells that can be used in the present invention include immortalized hybridoma cells, NS / 0 myeloma cells, 293 cells, Chinese hamster ovary (CHO) cells, HeLa cells, Cap cells (cells derived from human amniotic fluid) and CoS cells.
[0030] In this article, the term "Sanger sequencing" refers to the dideoxy chain termination method, and the reaction system includes target DNA fragments, deoxynucleotide triphosphates (dNTPs), dideoxynucleotide triphosphates (ddNTPs), sequencing primers and DNA polymerase. The core of the sequencing reaction is the ddNTPs used: due to the lack of 3'-OH groups, they do not have the ability to connect with another dNTP to form a phosphodiester bond, and these ddNTPs can be used to terminate the extension of the DNA chain. In addition, these ddNTPs are connected to radioactive isotopes or fluorescent labeling groups, so they can be detected by automated instruments or gel imaging systems. Early sequencing based on the Sanger method set up four parallel sequencing reactions, each of which included target fragments, DNA polymerase, sequencing primers, four dNTPs and a specific type of fluorescent (or radioactive isotope) labeled ddNTP (i.e., ddATP, ddGTP, ddCTP and ddTTP in different reactions). Through this configuration, the DNA chain will terminate at A, G, C and T positions in different reactions, and form DNA fragments of different lengths. These fragments can then be separated and displayed by gel electrophoresis. Denaturing acrylamide electrophoresis has four lanes, each corresponding to a base. After the electrophoresis, the X-ray film or gel image can be read by radioautography or ultraviolet development. Each dark band in the image represents the result of a DNA fragment with chain termination after the incorporation of a dideoxynucleotide (ddATP, ddGTP, ddCTP, ddTTP). The relative position of the different dark bands between the four lanes can be used to read (from bottom to top) the DNA sequence to obtain the base arrangement order of the target fragment. With the development of Sanger sequencing technology, the labeling technology of ddNTP has been greatly improved. Different types of ddNTP can be labeled with different fluorescent groups, and these fluorescent groups have the same excitation wavelength and different emission wavelengths, so they appear as different colors optically. Therefore, the sequencing reaction can be carried out in one system, meeting the industry's requirements for increasing sequencing speed, automation and throughput. Sanger sequencing is easy to operate and is therefore widely used. Sanger sequencing can now be performed in highly automated sequencers, including Life Technologies' 3130xL, 3730xL, 3500Dx and 3500Dx xL sequencers and Beckman's GeXP genetic analysis system. This type of system can measure DNA fragments up to 600-1000bp in length, and has good processing of repetitive sequences and polymerized sequences, with high sequence accuracy.
[0031] The present invention provides an isolated nucleic acid, an expression vector, a recombinant cell, a marker, a detection reagent, a kit and their uses in preparing a diagnostic product, which will be described in detail below.
[0032] Isolated nucleic acid, expression vector, recombinant cell
[0033] In one aspect of the present invention, the present invention provides an isolated nucleic acid. According to an embodiment of the present invention, the isolated nucleic acid includes an ACRBP mutant gene; wherein, compared with the ACRBP gene shown in the nucleotide sequence of SEQ ID NO:1, the mutation site of the ACRBP mutant gene is c.1091T>C.
[0034] In this article, the term "c.1091T>C" refers to a mutation in which the base 6749675 (located in the ACRBP gene) on chromosome 12 of the human GRCh37 version of the genome is converted from thymine (T) to cytosine (C). The specific information of the site mutation is NM_032489, c.1091T>C, which is a missense mutation that destroys the highly conserved amino acid site L364 of ACRBP.
[0035] Herein, the nucleotide sequence of the ACRBP gene is shown in SEQ ID NO:1.
[0036]
[0037] TGTGATCCAGGACTTCCCGGCCTTAGCCTGACGGGCTTCCCAGCTCTTCCAGTGCCTT
[0038] CCCTGCTCAATTAAATCAACTTGGCTCCCCGTTCCCCTGAGTTACCTCCCCTGTGGAAT
[0039] GACCTGTTGTTTTAGATCCAGGCCTCTCCTCCTGTAGTTAGCAGGGAAAACCAAGGCA
[0040] AGGAAAAGTAAGGGCAGCTGAAGCAAGGGCTGGTAGCTGAGCTGGGGGGCCCATGT
[0041] CCAGCTCTTGTCCCTGGGCCCCTTGATCTGGAATGGGGAGGCGAGGTCCAAAGAAGG
[0042] CAGTGACTCACTTCCCCCTTCCCTTATCTACCATTACCAGAAAAATCCTTGACATCAGG
[0043] CCACTAATCGGGTCCCTGTCCCATGTTCTGGACCCTTATCTACCCCGTCCTGCCCCATT
[0044] CCCGCTTCCTCAGCCACTTTCCCAGTAAGCTGACTGGCAGCCTCATACTCTCCCAGGC
[0045] TCCTGGCTTCTTCCCAGCAACCTGTGACAGAGCGGCAGGGGAAAGGCAGAGGGAAA
[0046] GCGGAGTGAGGGGCCGCCTGTGTGTGGAAGACCTGGGTCTTGGGCCACACCCTGCCC
[0047] CTGGCTCTGCCCTAGCAGATATTCCCTGGAGTGCTGCTGCCTGGTGAGGCTTCTGATAC
[0048] CCTCTTCCCTCTCTCTGGCTCTTGGCTTAGATTTGTGACACAGACTATATCCAGTACCC
[0049] AAACTACTGTTCCTTCAAAAGCCAGCAGTGTCTGATGAGAAACCGCAATCGGAAGGT
[0050] GAGCACCCCTGCCCTGCCCCTCCTTCTCCCAGCACCCCCTCAATCAGTCACCATAACT
[0051] GGTCTATTCTGAGGCCCCCTCTGCGAGCAGCTAGGATGTGGAAAGCGGTTCCTGCTTG
[0052] CATCTCTGGGGCAGAGGCCTCCACCAGCAGGCTCTCCTCCATTCCTCCAGTCCTGGCG
[0053] GAAGCAAGGCCCTCCTAGGCAGCTGGTGGATAACAGAGGAGGGTCCTAAGAGCACC
[0054] ACAGGAAGAACCCTTGGCTGGGCCAGGACTTGGACGTTGAGGTCTCGGTCTGTCTCC
[0055] TCTTCTTACTCACCAAGTAGCCTGGGATGAGGCACTTCCCCCTCTGAGCCTCAGCCGC
[0056] CTGTTTCTGCATGAAAGGGGTTGGGCTGCTTGATGTCTCCTCTGGCTTTAAAAACCCA
[0057] CATTTGAGTTTCCTCCTTCCCTCTACTGCCCTGTGCCCATGCCTGCCCACCTCTCGTTC
[0058] TTTTGGGCTTCTGACACCTCCCCTCCTCCCCACTCCTGGCACCTGGCTCTGTGATACAG
[0059] ACCGTCTGCACTGAATCTCTGTGTAGGTGTCCCGCATGAGATGTCTGCAGAATGAGAC
[0060] TTACAGTGCGCTGAGCCCTGGCAAAAGTGAGGACGTTGTGCTTCGATGGAGCCAGGA
[0061] GTTCAGCACCTTGACTCTAGGCCAGTTCGGATGAGCTGGCGTCTATTCTGCCCACACC
[0062] CCAGCCCAACCTGCCCACGTTCTCTATTGTTTTGAGACCCATTGCTTTCAGGCTGCCC
[0063] CTTCTGGGTCTGTTACTCGGCCCCTACTCACATTTCCTTGGGTTGGAGCAACAGTCCC
[0064] AGAGAGGGCCACGGTGGGAGCTGCGCCCTCCTTAAAAGATGACTTTACATAAAATGTT
[0065] GATCTTCA (SEQ ID NO: 1).
[0066] In this article, the term "missense mutation" refers to a codon encoding a certain amino acid that is replaced by a base and becomes a codon encoding another amino acid, thereby changing the type and sequence of amino acids in the polypeptide chain. The result of a missense mutation usually causes the polypeptide chain to lose its original function, and many protein abnormalities are caused by missense mutations.
[0067] In an optional embodiment of the present invention, the isolated nucleic acid can be used as a marker for diagnosing male infertility caused by sperm acrosome abnormalities.
[0068] According to an embodiment of the present invention, the nucleic acid molecule includes DNA or RNA. For expression vectors used to construct recombinant cells, it is preferred that the nucleic acid is DNA, because DNA is more stable and easy to operate relative to RNA. It should be noted that for the nucleic acid molecules mentioned herein, those skilled in the art should understand that they actually include any one of the complementary double strands, or two. For convenience, in this article, although only one strand is given in most cases, another strand complementary thereto is actually disclosed. In addition, the molecular sequence in the present invention is in the form of DNA or RNA, and disclosing one of them means that the other is also disclosed.
[0069] In the second aspect of the present invention, the present invention proposes an expression vector. According to an embodiment of the present invention, the expression vector carries the isolated nucleic acid described in the first aspect. When the above-mentioned nucleic acid molecule is connected to the expression vector, the nucleic acid molecule can be directly or indirectly connected to the control elements on the expression vector, as long as these control elements can control the translation and expression of the nucleic acid molecule. Of course, these control elements can come directly from the expression vector itself, or they can be exogenous, that is, they are not from the expression vector itself. Of course, the nucleic acid molecule can be operably connected to the control element. In this article, "operably connected" means connecting the exogenous gene to the expression vector so that the control elements in the expression vector, such as transcription control sequences and translation control sequences, etc., can play their expected functions of regulating the transcription and translation of the exogenous gene. Commonly used expression vectors can be, for example, plasmids, bacteriophages, etc.
[0070] In some specific embodiments of the present invention, the expression vector is a eukaryotic expression vector, a prokaryotic expression vector, a virus or a bacteriophage.
[0071] In an optional embodiment of the present invention, the expression vector is a plasmid expression vector.
[0072] In the third aspect of the present invention, the present invention provides a recombinant cell. According to an embodiment of the present invention, the recombinant cell carries the isolated nucleic acid described in the first aspect of the invention or the expression vector described in the second aspect. According to an embodiment of the present invention, the recombinant cell is obtained by introducing the expression vector described in the second aspect into a host cell.
[0073] It should be noted that the cells of the present invention are not particularly limited and can be prokaryotic cells, eukaryotic cells or bacteriophages. The prokaryotic cells can be Escherichia coli, Bacillus subtilis, Streptomyces or Proteus mirabilis, etc. The eukaryotic cells include fungi such as Pichia pastoris, Saccharomyces cerevisiae, Schizosaccharomyces pombe, Trichoderma, insect cells such as armyworm, plant cells such as tobacco, and mammalian cells such as BHK cells, CHO cells, COS cells, and myeloma cells.
[0074] In an optional embodiment of the present invention, the type of the cell is not particularly limited, for example, it can be an Escherichia coli cell, a mammalian cell, wherein the mammalian cell includes a BHK cell, a CHO cell, a NSO cell or a COS cell, and does not include an animal germ cell, a fertilized egg or an embryonic stem cell. Preferably, the cell is derived from a non-human mammal.
[0075] Markers, detection reagents, kits and uses thereof
[0076] The fourth aspect of the present invention is the use of the isolated nucleic acid described in the first aspect of the present invention as a marker for diagnosing male infertility caused by sperm acrosome abnormalities.
[0077] In a fifth aspect of the present invention, the present invention provides a marker. According to an embodiment of the present invention, the marker includes at least one of the following mutant genes: an ACRBP mutant gene, and compared with the ACRBP gene shown in the nucleotide sequence of SEQ ID NO: 1, the mutation site of the ACRBP mutant gene is c.1091T>C. The marker of the embodiment of the present invention can effectively diagnose whether the patient suffers from male infertility caused by sperm acrosome abnormality, and the detection reagents and kits for detecting the above markers have the advantages of high diagnostic specificity and high accuracy.
[0078] In a sixth aspect of the present invention, the present invention provides a detection reagent. According to an embodiment of the present invention, the detection reagent comprises the isolated nucleic acid described in the first aspect of the invention or the marker reagent described in the fifth aspect of the invention. The detection reagent according to the embodiment of the present invention can effectively diagnose male infertility caused by sperm acrosome abnormalities, and has the advantages of high diagnostic specificity and high accuracy.
[0079] In an optional embodiment of the present invention, the reagent is a primer set for detecting ACRBP mutant gene.
[0080] In an optional embodiment of the present invention, the primer set includes at least one of the following primer pairs:
[0081] Upstream primer GCTGGTGATAAAGATTTGGG and downstream primer TAGATACCTGGTTGCCGATG.
[0082] Therefore, the accuracy of detecting the above-mentioned markers can be further improved, thereby further improving the specificity and accuracy of diagnosing male infertility caused by sperm acrosome abnormalities.
[0083] In a seventh aspect of the present invention, the present invention provides a kit. According to an embodiment of the present invention, the kit comprises the detection reagent according to the sixth aspect of the invention. The detection reagent according to the embodiment of the present invention can effectively diagnose male infertility caused by sperm acrosome abnormality, and has the advantages of high diagnostic specificity and high accuracy.
[0084] In an optional embodiment of the present invention, the kit further comprises:
[0085] (1) Genomic DNA extraction reagents;
[0086] (2) polymerase chain reaction solution;
[0087] (3) Sequencing system reagents;
[0088] (4) Positive control samples and negative control samples.
[0089] Among them, genomic DNA extraction reagents can be purchased from commercial reagents such as TIANGEN and QIAGEN.
[0090] The detection system polymerase chain reaction system includes: a reaction mixture can be purchased from commercial reagents such as QIAGEN, and a polymerase chain reaction solution containing 10 μM of upstream and downstream primers for detecting the c.1091T>C mutation of the ACRBP gene.
[0091] In an eighth aspect of the present invention, the present invention provides a use of the detection reagent described in the sixth aspect or the kit described in the seventh aspect in the preparation of a diagnostic product, wherein the diagnostic product is used to diagnose male infertility caused by sperm acrosome abnormalities.
[0092] The scheme of the present invention will be explained below in conjunction with the embodiments. It will be appreciated by those skilled in the art that the following embodiments are only used to illustrate the present invention and should not be considered as limiting the scope of the present invention. Where specific techniques or conditions are not indicated in the embodiments, the techniques or conditions described in the literature in this area or the product specifications are used. The reagents or instruments used are not indicated by the manufacturer and are all conventional products that can be obtained commercially.
[0093] Example 1: Screening of ACRBP gene c.1091T>C mutation
[0094] 1. In accordance with relevant national policies and regulations and with the informed consent of the subjects, whole exome sequencing was performed on the peripheral blood genomic DNA of a patient with male infertility caused by sperm acrosome abnormalities. Genetic screening was performed using the Pedminer online tool (https: / / mcg.ustc.edu.cn / bsc / pedminer / ). It was found that the patient carried a homozygous mutation of the ACRBP gene c.1091T>C, which had not been detected in the population in the 1000 Genomes Database.
[0095] 2. Furthermore, the inventors designed a set of primer pairs targeting the mutation site of the above-mentioned ACRBP gene, including primers for detecting the c.1091T>C mutation of the ACRBP gene, the sequence of the upstream primer is GCTGGTGATAAAGATTTGGG (SEQ ID NO: 2), and the sequence of the downstream primer is TAGATACCTGGTTGCCGATG (SEQ ID NO: 3).
[0096] 3. Furthermore, the present invention designs a kit for detecting acrosomal protein ACRBP gene mutation, including a genomic DNA extraction reagent (TIANGEN or QIAGEN), a polymerase chain reaction solution (QIAGEN, which is used to cooperate with the upstream and downstream primers for detecting the ACRBP gene c.1091T>C mutation, wherein 10 μM of polymerase chain reaction solution is added to each pair of primers), sequencing system reagents (sequencing template, BigDye (2.5X) (Applied Biosystems, 4337458), and sequencing primers (3.2 pmol of the upstream primer or downstream primer for detecting the ACRBP gene c.1091T>C mutation designed in step 2 of this embodiment).
[0097] The above kit is used to detect the mutant gene of the peripheral blood genomic DNA of the male infertility patient caused by sperm acrosome abnormality in step 1, the patient's parents and the patient's fertile brothers. The specific steps are as follows:
[0098] 3.1 Steps for extracting genomic DNA from blood:
[0099] (1) Use EDTAK anticoagulant tube (BD, 367525) to extract 300 μL of blood, mix thoroughly, add 750 μL of FG1 red blood cell lysis buffer (FlexiGene DNA Kit, FQIAGEN, 51206), invert and mix 5 times, centrifuge at 10,000 g for 20 seconds, remove the supernatant, and keep the white blood cell pellet (red blood cells do not have nuclei, and red blood cells need to be removed before extracting genomic DNA). (2) Add 200 μL of proteinase K / FG2 buffer (FlexiGene DNA Kit, FQIAGEN, 51206) (1:100), vortex until thoroughly mixed, incubate at 65°C for 5 minutes, and the solution turns olive green (this color indicates that the protein reaction in the cells in (1) is complete with proteinase K digestion). (3) Add 200 μL of isopropanol, invert dozens of times until a flocculent precipitate appears, centrifuge at 10,000 g for 3 minutes, and remove the supernatant. (4) Add 75% ethanol, gently vortex and wash the precipitate for 5 seconds, centrifuge at 10,000 g for 3 minutes, and remove the supernatant. (5) Air dry for 15 minutes, add TE buffer to resuspend the precipitate, incubate at 65°C for 1 hour, and incubate at room temperature overnight. (6) Use Qubit 4.0 instrument (Invitrogen) to measure the DNA concentration to determine whether the genomic DNA extraction is successful. If the measured concentration is greater than 5 ng / μL, the next step of the reaction can be carried out.
[0100] 3.2 The preparation method of polymerase chain reaction solution is as follows:
[0101]
[0102] The reaction conditions are as follows:
[0103]
[0104] 3.3 The preparation method of Sanger sequencing reaction solution is as follows:
[0105]
[0106] The reaction conditions are as follows:
[0107]
[0108] 3.4 Sanger sequencing result judgment
[0109] The sequencing results were compared with the standard reference sequence of the ACRBP gene downloaded from the GenBank database of NCBI (NM_032489, as shown in SEQ ID NO: 1), and the results were reported according to the mutation situation. The results showed that the whole exome sequencing results were correct, the patient's parents were heterozygous carrying the pathogenic mutation site, the patient was homozygous carrying the pathogenic mutation site, and the patient's fertile brother did not carry the pathogenic site, indicating that the above mutation sites were recessively co-segregated with the male infertility phenotype in the family.
[0110] 4. Analyze the harmfulness of the mutation at the gene mutation site obtained in step 1 of this example:
[0111] For the missense mutation c.1091T>C in the ACRBP gene, the mutation pathogenicity prediction software "Combined Annotation-Dependent Depletion (CADD)" predicts that this site is a highly conserved site in evolution, and the mutation harmfulness prediction score (Phred-scaled score) is 25.9, indicating that the mutation will have a significant harmful effect on the protein and gene function. Combined with the background technology, the acrosome protein ACRBP gene is a gene related to male reproductive function, and its mutation may cause sperm acrosome abnormalities, indicating that the ACRBP gene c.1091T>C is a pathogenic mutation that causes sperm acrosome abnormalities in patients.
[0112] Example 2: ACRBP gene c.1091T>C validation in normal male controls
[0113] This study was approved by the Ethics Committee of the First Affiliated Hospital of the University of Science and Technology of China, and after informed consent from the sampling subjects, peripheral blood samples of 538 male volunteers with normal fertility who had a second child due to female tubal factors were collected at the Reproduction and Genetics Branch of the First Affiliated Hospital. According to the steps of 3.1 blood genomic DNA extraction in Example 1, peripheral blood genomic DNA was extracted and sent to BGI for whole exome sequencing to obtain a whole exome sequencing data set for normal men. By screening the ACRBP gene c.1091T>C mutation in this data set, it was found that no normal males were homozygous for this mutation.
[0114] Example 3: Diagnostic Validation
[0115] Under the premise of obtaining informed consent from the patient and the male volunteers with normal fertility, peripheral blood samples were collected from a male infertile patient with sperm acrosome abnormality and 100 male volunteers with normal fertility. The genomes of the above peripheral blood samples were extracted and tested according to the method in step 3 of Example 1. After sequencing, it was found that the patient carried the homozygous mutation c.1091T>C of the ACRBP gene (the results are shown in Figure 1 , the homozygous genotype shown in the box presents a single peak graph), the peripheral blood samples of 100 male volunteers with normal fertility did not carry the homozygous mutation of the ACRBP gene c.1091T>C mutation, and the sequencing results of the corresponding sites in the sequencing abundance graph were consistent between the genotypes of male volunteers with normal fertility and the reference genotype.
[0116] In the description of this specification, the description with reference to the terms "one embodiment", "some embodiments", "example", "specific example", or "some examples" etc. means that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic representations of the above terms do not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described may be combined in any one or more embodiments or examples in a suitable manner. In addition, those skilled in the art may combine and combine the different embodiments or examples described in this specification and the features of the different embodiments or examples, without contradiction.
[0117] Although the embodiments of the present invention have been shown and described above, it is to be understood that the above embodiments are exemplary and are not to be construed as limitations of the present invention. A person skilled in the art may change, modify, replace and vary the above embodiments within the scope of the present invention.
Claims
1. An isolated nucleic acid, characterized in that Including ACRBP mutant gene; Compared with the ACRBP gene shown in the nucleotide sequence of SEQ ID NO: 1, the mutation site of the ACRBP mutant gene is c.1091T>C.
2. An expression vector, characterized in that: Carrying the isolated nucleic acid of claim 1.
3. A recombinant cell, characterized in that Carrying the isolated nucleic acid of claim 1 or the expression vector of claim 2; Optionally, the recombinant cell is obtained by introducing the expression vector into a host cell.
4. Use of the isolated nucleic acid according to claim 1 as a marker for diagnosing male infertility caused by sperm acrosome abnormalities.
5. A marker, characterized in that Includes at least one of the following mutant genes: ACRBP mutant gene, compared with the ACRBP gene shown in the nucleotide sequence of SEQ ID NO: 1, the mutation site of the ACRBP mutant gene is c.1091T>C.
6. A detection reagent, characterized in that: include: A reagent for detecting the isolated nucleic acid according to claim 1 or the marker according to claim 5.
7. The detection reagent according to claim 6, characterized in that The reagent is a primer set for detecting ACRBP mutant gene; Optionally, the primer set includes at least one of the following primer pairs: Upstream primer GCTGGTGATAAAGATTTGGG and downstream primer TAGATACCTGGTTGCCGATG.
8. A kit, characterized in that: include: The detection reagent according to claim 6 or 7.
9. The kit according to claim 8, characterized in that Further comprising at least one of the following reagents: dNTPs, Taq enzyme and PCR reaction buffer.
10. Use of the detection reagent according to claim 6 or 7 or the kit according to claim 8 or 9 in the preparation of a diagnostic product for diagnosing male infertility caused by sperm acrosome abnormalities.
